Evidence map›Paper›PMID 28978352›Full record

ArticleArthritis research & therapy2017

Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).

Tomohiro Shimizu, Hyo Jin Choi, Ursula Heilmeier, Matthew Tanaka, Andrew J Burghardt, Jingshan Gong, Nattagan Chanchek, Thomas M Link, Jonathan Graf, John B Imboden and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Tomohiro ShimizuDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA. simitom@wg8.so-net.ne.jp.
Hyo Jin ChoiDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Ursula HeilmeierDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Matthew TanakaDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Andrew J BurghardtDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Jingshan GongDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Nattagan ChanchekDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Thomas M LinkDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
Jonathan GrafDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
John B ImbodenDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Xiaojuan LiDepartment of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, 185 Berry Street, Suite 350, San Francisco, CA, 94107, USA.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough one study showed minimal progression of erosions in patients with rheumatoid arthritis (RA) one year after TNFα inhibition therapy, no studies have investigated very early bone changes after initiation of anti-TNFα treatment. We investigated the effects of 3-month anti-TNFα treatment on bone erosion progression and bone microarchitecture in RA patients using high-resolution peripheral quantitative computed tomography (HR-pQCT).

methodsPatients with RA (n = 27) (17 in the anti-TNFα and 10 in the MTX-only group) underwent assessment of disease activity score in 28 joints (DAS-28), radiographs, 3-T magnetic resonance imaging (MRI) and HR-pQCT of metacarpophalangeal and wrist joints at baseline and 3 months. HR-pQCT-derived erosion volume, joint volume/width and bone microarchitecture were computed and joint destruction was assessed using Sharp and RAMRIS scorings on radiographs and MRI, respectively.

resultsOverall, 73 erosions were identified by HR-pQCT at baseline. Over 3 months, the anti-TNFα group had decreased mean erosion volume; increased erosion volume was observed in one clinical non-responder. The MTX-only group in contrast, trended toward increasing erosion volume despite low disease activity. In the anti-TNFα group, joint-space width and volume of MCP joints decreased significantly and was positively correlated with erosion volume changes (R

conclusionsUsing HR-pQCT, our data suggest that anti-TNFα treatment prevents erosion progression and deterioration of bone microarchitecture within the first 3 months of treatment, one patient not responding to treatment, had significant progression of bone erosions within this short time period. Patients with low disease activity scores (<3.2) can have continuous HR-pQCT-detectable progression of erosive disease with MTX treatment only. HR-pQCT can be a sensitive, powerful tool to quantify bone changes and monitor RA treatment short term (such as 3 months).

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidBone and BonesCertolizumab PegolFemaleHumansMaleMetacarpophalangeal JointMethotrexateMiddle AgedTomography, X-Ray ComputedTumor Necrosis Factor-alphaWrist JointAntirheumatic AgentsCertolizumab PegolMethotrexateTNF protein, humanTumor Necrosis Factor-alphaAnti-tumor necrosis factor alphaBone erosionHigh-resolution peripheral quantitative computed tomographyRheumatoid arthritis

Identifiers

PMID28978352
PMCPMC5628475
OpenAlexW2762762855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.